Emerging oral drugs for psoriasis

Bibliography

• Kivelevitch DN, Hebeler KR, Patel M, et al. Emerging topical treatments for psoriasis. Expert Opin Emerg Drugs 2013;18(4):523-32
   PubMed Web of Science ®Google Scholar
• Patel M, Day A, Warren RB, et al. Emerging therapies for the treatment of psoriasis. Dermatol Ther (Heidelb) 2012;2(1):16
   PubMedGoogle Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361(5):496-509
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64
   PubMed Web of Science ®Google Scholar
• Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 2014;74(4):423-41
   PubMed Web of Science ®Google Scholar
• LLC MB. Medical advances may help improve psoriasis outcomes. Life Science Digest 2012;1-14
   Google Scholar
• Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med 2014;4:8
   PubMed Web of Science ®Google Scholar
• Roth MM. Pregnancy dermatoses: diagnosis, management, and controversies. Am J Clin Dermatol 2011;12(1):25-41
   PubMed Web of Science ®Google Scholar
• Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol 1989;21(5 Pt 1):985-91
   PubMed Web of Science ®Google Scholar
• Bowcock AM, Barker JN. Genetics of psoriasis: the potential impact on new therapies. J Am Acad Dermatol 2003;49(2 Suppl):S51-6
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ, Turka LA, Mitra RS, et al. Direct and indirect control of T-cell activation by keratinocytes. J Invest Dermatol 1995;105(1 Suppl):25S-9S
   PubMed Web of Science ®Google Scholar
• Becher B, Pantelyushin S. Hiding under the skin: interleukin-17-producing gammadelta T cells go under the skin? Nat med 2012;18(12):1748-50
   PubMed Web of Science ®Google Scholar
• Krueger JG. Hiding under the skin: a welcome surprise in psoriasis. Nat med 2012;18(12):1750-1
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356(6):580-92
   PubMed Web of Science ®Google Scholar
• Zhu B, Edson-Heredia E, Cameron GS, et al. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2013;169(6):1337-41
   PubMed Web of Science ®Google Scholar
• Colombo MD, Cassano N, Bellia G, et al. Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. ScientificWorldJournal 2013;2013:805705
   PubMed Web of Science ®Google Scholar
• Ng LC, Lee YY, Lee CK, et al. A retrospective review of methotrexate-induced hepatotoxicity among patients with psoriasis in a tertiary dermatology center in Malaysia. Int J Dermatol 2013;52(1):102-5
   PubMed Web of Science ®Google Scholar
• Hsu L, Armstrong AW. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J Immunol Res 2014;2014:283617
   PubMed Web of Science ®Google Scholar
• Pardasani AG, Feldman SR, Clark AR. Treatment of psoriasis: an algorithm-based approach for primary care physicians. Am Fam Physician 2000;61(3):725-33
   PubMed Web of Science ®Google Scholar
• Taheri A, Cantrell J, Feldman SR. Tachyphylaxis to topical glucocorticoids; what is the evidence? Dermatol Online J 2013;19(7):18954
   PubMedGoogle Scholar
• Ryan C, Korman NJ, Gelfand JM, et al. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol 2014;70(1):146-67
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85
   PubMed Web of Science ®Google Scholar
• Salim A, Tan E, Ilchyshyn A, et al. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006;154(6):1169-74
   PubMed Web of Science ®Google Scholar
• Brownell I, Strober BE. Folate with methotrexate: big benefit, questionable cost. Br J Dermatol 2007;157(1):213
   PubMed Web of Science ®Google Scholar
• Sarkar R, Chugh S, Garg VK. Acitretin in dermatology. Indian J Dermatol Venereol Leprol 2013;79(6):759-71
   PubMed Web of Science ®Google Scholar
• Kuijpers AL, van Dooren-Greebe JV, van de Kerkhof PC. Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis. Dermatology 1997;194(1):88-90
   PubMed Web of Science ®Google Scholar
• Saurat JH. Side effects of systemic retinoids and their clinical management. J Am Acad Dermatol 1992;27(6 Pt 2):S23-8
   PubMed Web of Science ®Google Scholar
• McNamara PJ, Jewell RC, Jensen BK, et al. Food increases the bioavailability of acitretin. J Clin Pharmacol 1988;28(11):1051-5
   PubMed Web of Science ®Google Scholar
• Belge K, Bruck J, Ghoreschi K. Advances in treating psoriasis. F1000Prime Rep 2014;6:4
   PubMedGoogle Scholar
• Aslam A, Griffiths CE. Drug therapies in dermatology. Clin med 2014;14(1):47-53
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126(10):2194-201
   PubMed Web of Science ®Google Scholar
• Lebwohl M. New developments in the treatment of psoriasis. Arch Dermatol 2002;138(5):686-8
   PubMed Web of Science ®Google Scholar
• Irla N, Navarini AA, Yawalkar N. Alitretinoin abrogates innate inflammation in palmoplantar pustular psoriasis. Br J Dermatol 2012;167(5):1170-4
   PubMed Web of Science ®Google Scholar
• David M, Akerman L, Ziv M, et al. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol 2012;26(3):361-7
   PubMed Web of Science ®Google Scholar
• Feige E, Mendel I, George J, et al. Modified phospholipids as anti-inflammatory compounds. Curr Opin Lipidol 2010;21(6):525-9
   PubMed Web of Science ®Google Scholar
• Ismail N, Collins P, Rogers S, et al. Drug survival of fumaric acid esters for psoriasis: a retrospective study. Br J Dermatol 2014;171(2):397-402
   PubMed Web of Science ®Google Scholar
• Ryan C, Menter A. Ponesimod-a future oral therapy for psoriasis? Lancet 2014;384(9959):2006-8
   PubMed Web of Science ®Google Scholar
• Kadmon. Jefferies healthcare conference, New York City. In: 2014
   Google Scholar
• Chang BY, Zhao F, He X, et al. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol 2009;183(3):2183-92
   PubMed Web of Science ®Google Scholar
• Ortiz-Ibanez K, Alsina MM, Munoz-Santos C. Tofacitinib and other kinase inhibitors in the treatment of psoriasis. Actas Dermosifiliogr 2013;104(4):304-10
   PubMedGoogle Scholar
• Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012;167(3):668-77
   PubMed Web of Science ®Google Scholar
• A Phase 3, multi site, randomized, double blind, placebo controlled study of the efficacy and safety comparing CP- 690,550 and etanercept in subjects with moderate to severe chronic plaque psoriasis. 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01241591 [Last accessed 2 November 2014]
   Google Scholar
• A study to evaluate the effects and safety of treatment, treatment withdrawal, followed by re-treatment with CP-690,550 in subjects with moderate to severe chronic plaque psoriasis. 2014. Available from: http://clinicaltrials.gov/ct2/show/results/NCT01186744 [Last accessed 2 November 2014]
   Google Scholar
• Meier FM, McInnes IB. Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety. Best Pract Res Clin Rheumatol 2014;28(4):605-24
   PubMed Web of Science ®Google Scholar
• Phase IIa randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase (JAK) inhibitor, in patients with moderate-to-severe psoriasis. In: 3rd World Psoriasis & Psoriatic Arthritis Conference 2012: ‘‘Psoriasis – a global health challenge’”; 27 July 1 2012; Stockholm, Sweden
   Google Scholar
• Study to evaluate safety and effectiveness of oral apremilast (CC-10004) in patients with moderate to severe plaque psoriasis (ESTEEM 1). 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01194219 [Last accessed 2 November 2014]
   Google Scholar
• Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005;10(22):1503-19
   PubMed Web of Science ®Google Scholar
• Papp K GC, Leonardi C, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from the randomized treatment withdrawal phase of a phase 3, randomized, controlled trial (ESTEEM 1). J Am Acad Dermatology 2014;70:Suppl 1:AB164
   Google Scholar
• Papp KA, Kaufmann R, Thaci D, et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol 2013;27:e376-83
   PubMed Web of Science ®Google Scholar
• Tan J, Maari C, Nigen S, et al. Open-label exploratory study of acitretin for the treatment of severe chronic hand dermatitis. J Dermatolog Treat 2014;1-3
   PubMedGoogle Scholar
• Trial of CF101 to treat patients with psoriasis. 2014. Available from: http://clinicaltrials.gov/show/NCT01265667 [Last accessed 2 November 2014]
   Google Scholar
• Mease PK GD, Adebajo AO, et al. Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: pooled safety analysis of three phase 3, randomized, controlled trials. In: American College of Rheumatology; 26-30 October 2013; San Diego, CA. 2013
   Google Scholar
• Varada S, Tintle SJ, Gottlieb AB. Apremilast for the treatment of psoriatic arthritis. Expert Rev Clin Pharmacol 2014;7(3):239-50
   PubMed Web of Science ®Google Scholar
• A proof of concept study comparing three doses of an oral solution of LEO 22811 with a placebo oral solution for the treatment of psoriasis vulgaris. 2011. Available from: http://clinicaltrials.gov/show/NCT01116895 [Last accessed 2 November 2014]
   Google Scholar
• Study to assess VB-201 in patients with psoriasis. 2011. Available from: http://clinicaltrials.gov/show/NCT01001468 [Last accessed 2 November 2014]
   Google Scholar
• Olsson T, Boster A, Fernandez O, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry 2014;85(11):1198-208
   PubMed Web of Science ®Google Scholar
• Study to evaluate Apo805K1 in subjects with moderate to severe chronic plaque psoriasis. 2013. Available from: http://clinicaltrials.gov/show/NCT01483924 [Last accessed 2 November 2014]
   Google Scholar
• A safety and tolerability study of KD025 treatment in subjects with moderately severe psoriasis vulgaris. 2014. Available from: http://clinicaltrials.gov/show/NCT02106195 [Last accessed 2 November 2014]
   Google Scholar
• Vaclavkova A, Chimenti S, Arenberger P, et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2014;384(9959):2036-45
   PubMed Web of Science ®Google Scholar